GGrantIndex
← Leaderboards

Joan H Schiller

University Of Wisconsin Madison

Google Scholar ↗PubMed ↗ORCID ↗
$7,395,575
Attributed
$7,395,575
Total exposure
21
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $885.6K · FY2005–16
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16

Funding mix

By agency

NIH$7,395,575 · 21

By mechanism

K12$2,272,388 · 1
U10$1,398,000 · 1
T32$1,204,210 · 1
M01$725,620 · 13
R01$717,875 · 1
K24$564,662 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Wisconsin Madison

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectNeoplasm /Cancer ChemotherapyCombination ChemotherapyNonsmall Cell Lung CancerHuman Therapy EvaluationDrug Screening /EvaluationClinical Trial Phase IPaclitaxelCis Platinum CompoundOncologyDosageSmall Cell Lung CancerTopotecanVinblastineAntineoplasticsBreast NeoplasmsCarboplatinAngiogenesis InhibitorsP53 Gene /ProteinEtoposideDrug Adverse EffectEducation Evaluation /PlanningPhysicians

Grant awards (57)

UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10$50,000
U10 · FY2016 · CA · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10$700,000
U10 · FY2015 · CA · contact PI
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10$648,000
U10 · FY2014 · CA · contact PI
Physician Scientist Oncology Training Program$237,578
T32 · FY2014 · CA · contact PI
Physician Scientist Oncology Training Program$156,120
T32 · FY2013 · CA · contact PI
Physician Scientist Oncology Training Program$189,740
T32 · FY2012 · CA · contact PI
Physician Scientist Oncology Training Program$253,900
T32 · FY2011 · CA · contact PI
Physician Scientist Oncology Training Program$245,242
T32 · FY2010 · CA · contact PI
Physician Scientist Oncology Training Program$121,630
T32 · FY2009 · CA · contact PI
NM-404 AS AN IMAGING AGENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER$8,068
M01 · FY2006 · RR · contact PI
Clinical Academic Oncologist Training Program$606,085
K12 · FY2005 · CA
Nano-Structure Surfaces and Liquid Crystal Analysis$129,451
R21 · FY2005 · CA
NM-404 AS AN IMAGING AGENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER$10,862
M01 · FY2005 · RR
SAFETY AND EFFICACY OF ABX-EGF, PACLITAXEL AND CARBOPLATIN IN NSCLC$3,371
M01 · FY2005 · RR
PILOT STUDY OF LIQUID CRYSTAL NANO-STRUCTURED SURFACES (LC/NS) ANALYSES$2,247
M01 · FY2005 · RR
INITIAL HUMAN SAFETY EVALUATION OF NM404$374
M01 · FY2005 · RR
Nano-Structure Surfaces and Liquid Crystal Analysis$129,494
R21 · FY2004 · CA
MID CAREER INVESTIGATOR AWARD$117,762
K24 · FY2004 · CA
ACADEMIC CLINICAL ONCOLOGIST TRAINING PROGRAM$87,405
K12 · FY2004 · CA
Initial Human Safety Evaluation of NM404$15,600
M01 · FY2004 · RR
Safety and Efficacy of ABT-510 Plus Combination Chemotherapy in NSCLC$6,933
M01 · FY2004 · RR
ACADEMIC CLINICAL ONCOLOGIST TRAINING PROGRAM$473,799
K12 · FY2003 · CA
CCNU in NSCLC Patients with Methylation of the MGMT Gene$234,974
R01 · FY2003 · CA
MID CAREER INVESTIGATOR AWARD$115,276
K24 · FY2003 · CA
ACADEMIC CLINICAL ONCOLOGIST TRAINING PROGRAM$391,285
K12 · FY2002 · CA
CCNU in NSCLC Patients with Methylation of the MGMT Gene$236,163
R01 · FY2002 · CA
NM-404 A Novel Imaging Agent in Lung Cancer$181,875
R21 · FY2002 · CA
MID CAREER INVESTIGATOR AWARD$112,862
K24 · FY2002 · CA
PHASE III RANDOMIZED STUDY OF INTENSIVE CISPLATIN AND VINBLASTIN +/- AMIFOSTINE$106,600
M01 · FY2002 · RR
PHASE I/II TRIAL OF AMIFOSTINE, HIGH DOSE CISPLATIN, AND DOCETAXEL IN NSCLC$106,600
M01 · FY2002 · RR
PHASE I TRIAL OF DOCETAXEL &K$106,600
M01 · FY2002 · RR
ACADEMIC CLINICAL ONCOLOGIST TRAINING PROGRAM$471,616
K12 · FY2001 · CA
CCNU in NSCLC Patients with Methylation of the MGMT Gene$246,738
R01 · FY2001 · CA
MID CAREER INVESTIGATOR AWARD$110,519
K24 · FY2001 · CA
PHASE I/II TRIAL OF AMIFOSTINE, HIGH DOSE CISPLATIN, AND DOCETAXEL IN NSCLC$106,600
M01 · FY2001 · RR
PHASE I TRIAL OF DOCETAXEL &K$106,600
M01 · FY2001 · RR
PHASE III RANDOMIZED STUDY OF INTENSIVE CISPLATIN AND VINBLASTIN +/- AMIFOSTINE$106,600
M01 · FY2001 · RR
PHASE I TRIAL OF DOCETAXEL &K$12,855
M01 · FY2001 · RR
PHASE III RANDOMIZED STUDY OF INTENSIVE CISPLATIN AND VINBLASTIN +/- AMIFOSTINE$12,855
M01 · FY2001 · RR
PHASE I/II TRIAL OF AMIFOSTINE, HIGH DOSE CISPLATIN, AND DOCETAXEL IN NSCLC$12,855
M01 · FY2001 · RR
ACADEMIC CLINICAL ONCOLOGIST TRAINING PROGRAM$242,198
K12 · FY2000 · CA
MID CAREER INVESTIGATOR AWARD$108,243
K24 · FY2000 · CA
SQUALAMINE PLUS CARBOPLATIN AND PACLITAXEL IN NSC LUNG C$72,000
R03 · FY2000 · CA
ZENECA ZD0473 COMBINED WITH TOPOTECAN IN PTS W REFRACTORY SOLID MALIGNANCIES$0
M01 · FY2000 · RR
ETOPOSIDE, CISPLATIN, AND PACLITAXEL IN EXTENSIVE SCLC$0
M01 · FY2000 · RR
ETOPOSIDE, CISPLATIN, AND PACLITAXEL IN EXTENSIVE SCLC$0
M01 · FY2000 · RR
MSI-1256F (SQUALAMINE LACTATE) , CARBOPLATIN, PACLITAXIL IN NONSMAL CELL LUNG CAN$0
M01 · FY2000 · RR
MSI-1256F (SQUALAMINE LACTATE) , CARBOPLATIN, PACLITAXIL IN NONSMAL CELL LUNG CAN$0
M01 · FY2000 · RR
ADENOVIRUS P53 IN BRONCHIO-ALVEOLAR CELL LUNG CARCINOMA$0
M01 · FY2000 · RR
ZENECA ZD0473 COMBINED WITH TOPOTECAN IN PTS W REFRACTORY SOLID MALIGNANCIES$0
M01 · FY2000 · RR
PHASE I TRIAL OF DOCETAXEL &K$0
M01 · FY2000 · RR
PHASE I TRIAL OF DOCETAXEL &K$0
M01 · FY2000 · RR
PHASE I/II TRIAL OF AMIFOSTINE, HIGH DOSE CISPLATIN, AND DOCETAXEL IN NSCLC$0
M01 · FY2000 · RR
PHASE I/II TRIAL OF AMIFOSTINE, HIGH DOSE CISPLATIN, AND DOCETAXEL IN NSCLC$0
M01 · FY2000 · RR
PHASE III RANDOMIZED STUDY OF INTENSIVE CISPLATIN AND VINBLASTIN +/- AMIFOSTINE$0
M01 · FY2000 · RR
PHASE III RANDOMIZED STUDY OF INTENSIVE CISPLATIN AND VINBLASTIN +/- AMIFOSTINE$0
M01 · FY2000 · RR
ADENOVIRUS P53 IN BRONCHIO-ALVEOLAR CELL LUNG CARCINOMA$0
M01 · FY2000 · RR